MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016

MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016

Background: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug inclusion and exclusion into the reimbursement lists in Russian Federation. The liner mathematical model of decision making was developed and adopted.Aim. Update the existing model using the results of...

Full description

Bibliographic Details
Main Authors:	A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum
Format:	Article
Language:	Russian
Published:	IRBIS LLC 2016-04-01
Series:	Фармакоэкономика
Subjects:	reimbursement drug list drug linear model formalized decision making
Online Access:	https://www.pharmacoeconomics.ru/jour/article/view/134

Similar Items

What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01)

Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study
by: Hong Zhu, et al.
Published: (2022-07-01)

Evaluation of alignment of the reimbursement medicines list for children in Albania with the WHO essential medicines list for children
by: E. Petro, et al.
Published: (2024-12-01)

The reimbursement decision speed for oncology new drugs in China and its determinant factors
by: Xingyue Zhu, et al.
Published: (2023-10-01)

New reimbursement criteria for lipid-lowering drugs
by: Mario Eandi
Published: (2011-06-01)

Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy
by: V. A. Lemeshko, et al.
Published: (2021-04-01)

The AIFA time-to-reimbursement: a comparison between the last two committees from 2015 to 2020
by: Paola Raimondo, et al.
Published: (2020-12-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of hypoglycemic drugs proposed for inclusion into the essential drug list in 2014-2016 in Russia
by: A. A. Mosikyan, et al.
Published: (2018-05-01)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01)

Drugs price and reimbursement regulation: comparators, endpoints and role of the cost-effectiveness
by: Claudio Jommi, et al.
Published: (2022-09-01)

Drug pricing and reimbursement decision making systems in Mongolia
by: Gereltuya Dorj, et al.
Published: (2017-12-01)

Impact of the therapeutic positioning report in the P&R process in Spain: analysis of orphan drugs approved by the European Commission and reimbursed in Spain from 2003 to 2019
by: Xavier Badia, et al.
Published: (2020-08-01)

Analysis of effectiveness criteria in pharmacoeconomic studies of antimicrobial agents proposed for inclusion in the Russian essential drug list in the 2014 -2016
by: Gomon Yu.M., et al.
Published: (2017-08-01)

Analysis of changes in drug reimbursement based on the example of the limit groups containing beta-2 adrenergic drugs in Poland in the years 2012-2021
by: Piotr Zbigniew Rykowski, et al.
Published: (2022-06-01)

Reimbursement process of medicinal products in Poland and in the world
by: Aneta Katarzyna Mela
Published: (2020-09-01)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
by: Di Wu, et al.
Published: (2022-04-01)

Health technology assessment and reimbursement of pharmaceuticals in Italy
by: F. V. Gorkavenko, et al.
Published: (2019-07-01)

Financial incentives for generic drugs: case study on a reimbursement program
by: Marcos Inocencio, et al.
Published: (2010-06-01)

Financial incentives for generic drugs: case study on a reimbursement program
by: Marcos Inocencio, et al.
Published: (2010-06-01)

Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey
by: Julie Polisena, et al.
Published: (2017-05-01)

Clinical aspects of reimbursement policies for orphan drugs in Central and Eastern European countries
by: Szczepan Jakubowski, et al.
Published: (2024-03-01)

Do reimbursement recommendation processes used by government drug plans in Canada adhere to good governance principles?
by: Rawson NS, et al.
Published: (2017-11-01)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
by: Andrew L Gray
Published: (2015-12-01)

Correlation between clinical trial endpoints of marketed cancer drugs and reimbursement decisions in China
by: Kexin Ling, et al.
Published: (2022-11-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
by: Ewa Stawowczyk, et al.
Published: (2019-11-01)

Analysis of oral hypoglycemic drugs that are subject to reimbursement in Ukraine
by: I. O. Vlasenko
Published: (2022-10-01)

A systematic review of moral reasons on orphan drug reimbursement
by: Bettina M. Zimmermann, et al.
Published: (2021-06-01)

ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
by: José Luis Poveda, et al.
Published: (2023-01-01)

The timelines for the price and reimbursement authorization in Italy 2018–2020
by: Valentina Gallo, et al.
Published: (2022-12-01)

The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia
by: V. V. Omelyanovsky, et al.
Published: (2018-11-01)

Analysis of organizational and medical documents and formulary lists regulating medical support of pregnant women
by: M. L. Syatynya, et al.
Published: (2012-12-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
by: Krzysztof Piotr Malinowski, et al.
Published: (2020-10-01)

Rozwiązania prawne w refundacji leków oraz produktów medycznych dla diabetyków na tle porównawczym w wybranych krajach europejskich
by: Marta Hylewska
Published: (2022-01-01)

Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871
by: V. V. Omelyanovskiy, et al.
Published: (2020-08-01)

Equivalent Modes of Reimbursement in Augmented Contests
by: Chen Cohen, et al.
Published: (2023-03-01)

The Impact of the Clinical Miscoding on Inpatient Reimbursement
by: Roghayeh Ershad Sarabi, et al.
Published: (2020-03-01)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
by: Sam Salek, et al.
Published: (2019-03-01)

Reimbursement measures in European countries – findings of a bibliometric literature review
by: Sabine Vogler, et al.
Published: (2015-12-01)